The Business Research Company’s report on the Irritable Bowel Syndrome (IBS) Treatment Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
How are market drivers shaping the future growth trajectory of the irritable bowel syndrome (ibs) treatment industry?
The rise in the prevalence of irritable bowel syndrome (IBS) is expected to propel the growth of the irritable bowel syndrome treatment market going forward. IBS is a chronic gastrointestinal disorder affecting the large intestine (colon). The rise in irritable bowel syndrome (IBS) prevalence is driven by poor lifestyles, bad eating habits, exposure to pollution, and increased stress levels. IBS treatment helps to reduce the severity and frequency of IBS symptoms, improve the quality of life, and enable individuals to manage their conditions better. For instance, according to the International Foundation for Gastrointestinal Disorders (IFFGD), a US-based non-profit education and research organization, about 5–10% of the global population are having IBS in 2023 and between 25 and 45 million people in the United States are affected by IBS. Therefore, the rise in the prevalence of irritable bowel syndrome (IBS) is driving the growth of the IBS treatment market.
Access Your Free Sample of the Global Irritable Bowel Syndrome (IBS) Treatment Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=11978&type=smp
What is the estimated market size of the irritable bowel syndrome (ibs) treatment sector by 2029, based on current forecasts?
The irritable bowel syndrome (IBS) treatment market size has grown rapidly in recent years. It will grow from $2.79 billion in 2024 to $3.07 billion in 2025 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to increasing prevalence of ibs, growing patient awareness, stress and lifestyle factors, patient advocacy and support groups, healthcare reimbursement policies
The irritable bowel syndrome (IBS) treatment market size is expected to see rapid growth in the next few years. It will grow to $4.93 billion in 2029 at a compound annual growth rate (CAGR) of 12.5%. The growth in the forecast period can be attributed to patient-centric healthcare models, microbial therapies, blockchain in healthcare, patient-reported outcomes (pros), regulatory fast-track programs, health data interoperability. Major trends in the forecast period include integration of digital health solutions, advancements in diagnostic technologies, increased research and development investments, collaborations and partnerships, emergence of non-pharmacological therapies.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=11978&type=smp
#Who are the top players in the irritable bowel syndrome (ibs) treatment market?
Major companies operating in the irritable bowel syndrome (IBS) treatment market include Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Novartis AG, AstraZeneca plc, Abbott Laboratories, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Astellas Pharma Inc., Biogen Inc., Bausch Health Companies Inc., Ironwood Pharmaceuticals Inc., Sebela Pharmaceuticals Inc., Prometheus Laboratories Inc., RedHill Biopharma Ltd., Ardelyx Inc., Cosmo Technologies Ltd., Renexxion Ireland Ltd., 4D Pharma plc, Biora Therapeutics Inc.
#What are the major trends in the irritable bowel syndrome (ibs) treatment market?
Product innovations have emerged as a key trend gaining popularity in the irritable bowel syndrome (IBS) market. Major irritable bowel syndrome (IBS) market players are concentrating their efforts on creating new and innovative, advanced products to strengthen their position in the market. For instance, in April 2022, Ardelyx, a US-based biotechnology company, launched IBSRELA, a first-in-class treatment for IBS-C in adults. It is the first and only NHE3 inhibitor available for treating adult irritable bowel syndrome with constipation (IBS-C). IBSRELA, the first Ardelyx medicine to receive FDA approval, is the first novel mechanism therapy for IBS-C (irritable bowel syndrome-constipation) to be developed in almost ten years, and it provides a significant new treatment option for constipation, bloating, and stomach pain that are symptoms of this crippling disorder.
Which geography holds the highest irritable bowel syndrome (ibs) treatment market share?
North America was the largest region in the irritable bowel syndrome (IBS) treatment market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the irritable bowel syndrome (IBS) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
How do different segments contribute to the overall expansion of the irritable bowel syndrome (ibs) treatment market?
The irritable bowel syndrome (IBS) treatment market covered in this report is segmented –
1) By Drug Type: Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Alosetron, Other Drugs
2) By Indication: IBS With Constipation, IBS With Diarrhea, IBS With Alternating Constipation And Diarrhea
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
4) By End-Users: Hospitals, Clinics, Homecare Settings
Subsegments:
1) By Lubiprostone: Chronic Idiopathic Constipation Treatment, Irritable Bowel Syndrome with Constipation (IBS-C) Treatment
2) By Linaclotide: IBS-C Treatment, Chronic Idiopathic Constipation Treatment
3) By Eluxadoline: IBS with Diarrhea (IBS-D) Treatment
4) By Rifaximin: IBS-D Treatment, Small Intestinal Bacterial Overgrowth (SIBO) Treatment
5) By Alosetron: Severe IBS-D Treatment for Women
6) By Other Drugs: Prucalopride, Tenapanor, Plecanatide
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11978
How is the irritable bowel syndrome (ibs) treatment market defined?
Irritable bowel syndrome (IBS) treatment refers to the various approaches and interventions aimed at treating gastrointestinal tract disorders, which are frequent disorders that affect the stomach and intestines. It is used to alleviate constipation, diarrhea, and abdominal symptoms, minimize the frequency and severity of flare-ups, and enhance overall well-being.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
